Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate-Reference-Cited by-同舟云学术

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Published:2020-09-07 Issue:10 Volume:72 Page:1621-1631
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Robinson Michael F.¹,Damjanov Nemanja²,Stamenkovic Bojana³,Radunovic Goran²,Kivitz Alan⁴,Cox Lori⁵,Manukyan Zorayr⁵,Banfield Christopher⁵,Saunders Michael⁵,Chandra Deepa⁵,Vincent Michael S.⁵,Mancuso Jessica⁶,Peeva Elena⁵,Beebe Jean S.⁵

Affiliation:

1. California Medical Research Associates Northridge

2. University of Belgrade School of Medicine Belgrade Serbia

3. Institute for Treatment and Rehabilitation Niska Banja and Nis University School of Medicine Nis Serbia

4. Altoona Center for Clinical Research Duncansville Pennsylvania

5. Pfizer, Inc. New York New York

6. Pfizer, Inc. Groton Connecticut

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link